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1. Introduction 
The current concept for prostaglandin (PC) bio- 
synthesis recently has been enlarged by the discovery 
of novel transformations of PG endoperoxides which 
are known as intermediates in the synthesis of the 
primary PG’s E, F,, and D [ 1 ] . Moreover the PG 
endoperoxides Ga and Ha (PGGa, PGH2) seem to be 
more potent than the PGs in platelet aggregation [2], 
inhibition of adenylate cyclase [3], and contraction 
of rabbit aorta [4] and human umbilical artery strips 
[ 51. Because of their short half lives in aqueous 
media (3-5 min) [l] , stable endoperoxide analogues 
were synthesized which are causing comparable effects 
in some biological systems [6-91. 
PGDa is biosynthesized by the PG synthetase system 
[lO,ll] and has been shown to have important 
biological activities [4,12,13]. In the platelet aggrega- 
tion system it even seems to counteract the endo- 
peroxides [2,12] . 
It should be of interest to know the properties of 
the endoperoxides and PGDz as substrates of 15 
hydroxyprostaglandin dehydrogenase (15-HPGDH, 
EC 1.1 .1.141) which is the key enzyme in biological 
inactivation of most prostaglandins [ 141. Recently 
Sun et al. [ 151 reported PGHa to be substrate of a 
1 S-HPGDH prepared from monkey lung, whereas 
PGGz and PGDz were not. Kinetic studies on PGHz 
are not published yet which may be due to its extreme 
lability. The present investigation has been performed 
to examine whether two chemically stable PGHa 
analogues and PGD2 are substrates of a NAD’-depen- 
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dent human placental 15-HPGDH and to compare 
their kinetics with those of PGEz and PGFao. 
2. Materials and methods 
The prostaglandin endoperoxide analogues (15s) 
hydroxy-9a,l lo-(epoxymethano)prosta-5Z,13E-dienoic 
acid (U-44069) and (15s)hydroxy-1 laQa-(epoxy- 
methano)prosta-5Z,13E-dienoic acid (U-46619) as 
well as PGEa, PGF20, and PGDa were generously 
supplied by Dr G. L. Bundy and Dr U. Axen, the 
Upjohn Company, Kalamazoo, Michigan, USA. NAD’, 
grade I, was purchased from Boehringer, Mannheim, 
and silica gel thin layer plates ‘DC-Karten SI’ from 
Biedel-de Haen, Seelze-Hannover. 
NAD’-dependent 15-HPGDH was purified from 
human placenta up to a specific activity of 5200 mHJ/ 
mg of protein (25°C optimal conditions) using a 
modification of the procedures described by Schlegel 
and Greep [16] and Junget al. [17]. 
Except of PGDz complete initial rate patterns were 
set up using the activity test system described in [ 171 : 
initial velocities were determined by measuring NADH 
formation at 340 nm in 0.1 M triethanolamine buffer 
(TRAP) at pH 7.4 and 37°C. NAD’ and PGFao were 
varied from 0.025 to 0.5 mM, PGEs from 0.0063 to 
0.1 mM, and U-44069 and U-46619 between 0.018 
and 0.28 mM. The kinetic patterns were evaluated 
according to Cleland [ 181. 
In order to study PGDz as substrate of 15-HPGDH 
2 I.tmol of PGD2, 2 pmol of NAD’, and 60 mIU of 
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enzyme were incubated in 0.1 M TRAP at pH 7.4 and 
37°C in a final volume of 2 ml. After 20 min the solu- 
tion was adjusted to pH 3.5 with 1 n HCl and extracted 
with ethylacetate. Spectra of the organic phase and its 
aqueous pH 8 extract were run from 2.50 to 750 nm 
in an Unicam SP 1800 double beam spectrophoto- 
meter. For thin-layer chromatography the dried ethyl- 
acetate extract was evaporated to dryness and redis- 
solved in ethanol. This solution was spotted on heat 
activated silica gel thin layer plates and chromato- 
graphed with benzene/dioxane/acetic acid (20:20: 1) 
for a total length of 14 cm [ 191. The plate was dried 
and developed in ammonia atmosphere or with 10% 
ethanolic phosphomolybdic acid or cut into slices 
and eluted with ethylacetate. Initial velocity studies 
with PGDs were performed at pH 8 and 37°C with a 
futed NAD’ concentration of 1 mM recording the 
formation of a product at 420 nm. PGDs was varied 
from 0.05 to 0.8 mM. All experiments were checked 
by omitting NAD’ or enzyme from the incubation 
mixture. 
Table 1 
Kinetic constants of human placental 15HPGDH 
PG VI KPG 
w (P% 
KPG 
&U 
KNAD 
h% 
KNAD 
&f 1 
PGE, * 100 3 10 
PGD,** 
COOH U-44069* 
.~\-r-‘ACOOH U46619* 
43 130 a) 
98 43 135 44 140 b) 
102 45 110 44 110 a) 
1 500 a) 
23 21 140 44 160 b) 
22 18 80 27 120 a) 
14 67 250 40 140 b) 
15 20 130 23 115 a) 
Kinetic constants which were calculated from sets of initial rate measurements performed atTiibingen are 
marked with a) at the end of the line. Those from experiments done at Ulm with the same enzyme solution 
are marked with b). For details see materials and methods. 
*These kinetic constants arc calculated from complete initial rate patterns at pH 7.4. 
**For PGD, only apparent constants can be given as it is a very poor substrate. At pH 8 PGD, was varied at 
a fixed NAD concentration of 1 mM. 
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3. Results 
The enzymatic conversion of PGD? by 1 SHPGDH 
at pH 7.4 and pH 8 resulted in an increase of absor- 
bance at 340 nm which is mostly due to NADH 
formation and in the production of a yellow com- 
pound with a maximum absorbance at 420 nm which 
is completely dependent on the presence of PGDz ,
NAD’, and enzyme. The yellow colour together with 
the absorbance at 420 nm disappears by acidifying 
the solution and reappears at alkaline pH values. This 
compound was less polar than PGDz on thin-layer 
chromatography. It was detected as a yellow spot in 
ammonia atmosphere or, after extraction from the 
plates, by its absorbance at 420 nm. Initial velocity 
studies at pH 8 - performed by recording the increase 
of absorbance at 420 nm - resulted in a linear Line- 
weaver-Burk plot [20]. The apparent Michaelis 
constant of PGDz (KkGDzapp) was found to be high 
and the maximum velocity very low compared to the 
constants of PGEz and PGF*, (table 1). 
From the complete initial rate patterns of 
15-HPGDH forward reaction with the substrates 
u-44069, U-46619, PGEz, and PGF2& intersecting 
double reciprocal primary plots were obtained which 
were linear within experimental error. The limiting 
Michaelis constants (Km), dissociation constants (KS), 
and extrapolated maximum velocities (V,) calculated 
from the primary plots and the linear intercept and 
slope replots are summarized in table 1. 
4. Discussion 
The two PGHz analfogues U-44069 and U-46619 in 
which one of the peroxide oxygens of PGHz is sub- 
stituted by a methylene group have a geometry 
approximating that of PGHz [6], Their effects on 
platelets, rabbit aorta, and airway resistance are 
comparable to those of the PG endoperoxides [8,9]. 
The present study demonstrates that they are sub- 
strates of a human placental 1 S-HPGDH with affinities 
to the enzyme being in the order of magnitude of 
PGFZa. Their V1 are considerably lower than those 
of PGEz and PGFZa (table 1). For monkey lung 
1 SHPGDH PGHZ itself seems to be a ‘better’ substrate 
[ 151, although a comparison is difficult because of a 
lack of kinetic studies and a possible conversion of 
PGH? into PGEz in the incubation mixture. If our 
data on the analogues are transferable to PGH? and to 
physiological conditions, it may be possible that PGHz 
- after an eventual release from the PG synthetase - is 
inactivated via the 15-HPGDH pathway before dramatic 
effects can be caused. 
Compared to PGHz the cyclic ethers U-44069 and 
U-466 19 have a considerably improved chemical 
stability. This is hardly true for their biochemical 
stability with respect to their metabolism by 15-HPGDH. 
If they are used for pharmacological studies their 
conversion into the 15-keto metabolites should be 
taken into account. 
These considerations are not significant in the case 
of PGDz which is no substrate of 15-HPGDH from 
monkey lung [ 151 and only a very poor one of the 
human placental enzyme (table 1). The yellow com- 
pound (2ma = 420 nm) is product of the dehydroge- 
nase reaction, as it was not formed when NAD’ or 
enzyme were omitted from the incubation mixture. 
This is further supported by the linear double reci- 
procal plot of the kinetic measurements at 420 nm. 
The colour and absorbance changes of the product 
between acidic and alkaline solutions may be explained 
by the pH-dependent formation of an enolate anion 
of 15-keto PGD2. Unfortunately we could not further 
identify this compound, because there was no 
reference of 15-keto PGDz available to us. 
The high KFD2 app for NAD’-dependent 15- 
HPGDH indicates that PGD2 can not be an inhibitor 
of the main metabolic pathway of PGE and PGF. 
Because of the high Km and low maximum velocity 
this enzyme can hardly be important in the physiolo- 
gical inactivation of PGD2. This is in good correlation 
with the prolonged biological activity of orally or 
intravenously given PGD2 as compared with PGEl 
[ 121. Therefore another pathway of elimination 
should exist for PGDz or it may occur as part of a 
pathological development. 
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